JP2012509344A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509344A5
JP2012509344A5 JP2011537608A JP2011537608A JP2012509344A5 JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5 JP 2011537608 A JP2011537608 A JP 2011537608A JP 2011537608 A JP2011537608 A JP 2011537608A JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5
Authority
JP
Japan
Prior art keywords
formulation
amino acid
acid sequence
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509344A (ja
JP5726085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065084 external-priority patent/WO2010059787A1/en
Publication of JP2012509344A publication Critical patent/JP2012509344A/ja
Publication of JP2012509344A5 publication Critical patent/JP2012509344A5/ja
Application granted granted Critical
Publication of JP5726085B2 publication Critical patent/JP5726085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011537608A 2008-11-20 2009-11-19 治療用タンパク質製剤 Active JP5726085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11654108P 2008-11-20 2008-11-20
US61/116,541 2008-11-20
PCT/US2009/065084 WO2010059787A1 (en) 2008-11-20 2009-11-19 Therapeutic protein formulations

Publications (3)

Publication Number Publication Date
JP2012509344A JP2012509344A (ja) 2012-04-19
JP2012509344A5 true JP2012509344A5 (OSRAM) 2015-04-02
JP5726085B2 JP5726085B2 (ja) 2015-05-27

Family

ID=41683048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537608A Active JP5726085B2 (ja) 2008-11-20 2009-11-19 治療用タンパク質製剤

Country Status (12)

Country Link
US (2) US20120027772A1 (OSRAM)
EP (1) EP2358393A1 (OSRAM)
JP (1) JP5726085B2 (OSRAM)
KR (1) KR101676887B1 (OSRAM)
CN (2) CN102281901A (OSRAM)
AU (1) AU2009316592B2 (OSRAM)
BR (1) BRPI0921947A2 (OSRAM)
CA (1) CA2737045C (OSRAM)
HK (1) HK1244426A1 (OSRAM)
IL (1) IL211670A (OSRAM)
MX (1) MX2011004748A (OSRAM)
WO (1) WO2010059787A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
RS56599B1 (sr) * 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
WO2015183989A1 (en) * 2014-05-27 2015-12-03 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
US20170096495A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
MA52202A (fr) * 2018-04-02 2021-02-17 Amgen Inc Compositions d'érénumab et utilisations de celles-ci
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP2003128575A (ja) * 2001-10-25 2003-05-08 Mochida Pharmaceut Co Ltd 脳腫瘍治療剤
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
DK1742966T3 (da) * 2004-04-22 2014-02-03 Agensys Inc Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2667019C (en) * 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor

Similar Documents

Publication Publication Date Title
JP2012509344A5 (OSRAM)
JP7472210B2 (ja) 有効性の改善および毒性の減少のための、抗体およびｓｎ－３８からなるイムノコンジュゲートの投薬
JP7245239B2 (ja) Ｒｏｒ１抗体免疫複合体
JP2015528818A5 (OSRAM)
ES2819573T3 (es) Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
JP2015527318A5 (OSRAM)
JP2015531750A5 (OSRAM)
ES2945533T3 (es) Inmunoconjugados con un enlace escindible intracelularmente
ES2892525T3 (es) Uso neoadyuvante de conjugados anticuerpo-fármaco
AU2014293670B2 (en) Antibody-SN-38 immunoconjugates with a CL2A linker
JP2019146572A5 (OSRAM)
JP2017503011A5 (OSRAM)
JP2017522861A5 (OSRAM)
JP2015523380A5 (OSRAM)
JP2015527319A5 (OSRAM)
CN105209068A (zh) 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
JP2011500725A5 (OSRAM)
WO2017004144A1 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
JP2011505371A5 (OSRAM)
JP2015529656A5 (OSRAM)
JP2016537399A5 (OSRAM)
WO2024145398A1 (en) Antibody drug conjugates
RU2016109247A (ru) Способы применения антител к lgr5
WO2025213130A1 (en) Antibody drug conjugates
ES2886927T3 (es) Inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A